Risk factors for the development of atrial fibrillation on ibrutinib treatment

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding

(2018) Giuseppe Boriani et al.   HEMATOLOGICAL ONCOLOGY

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study

(2018) Gianluigi Reda et al.   Journal of Hematology & Oncology

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

(2017) Jennifer R. Brown et al.   HAEMATOLOGICA

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

(2017) Jennifer R. Brown et al.   HAEMATOLOGICA

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

(2016) Darryl P. Leong et al.   BLOOD

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

(2016) Tait D. Shanafelt et al.   LEUKEMIA & LYMPHOMA

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

(2014) J. R. McMullen et al.   BLOOD

Insights Into Onco-Cardiology

(2013) Dimitrios Farmakis et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Atrial Fibrillation and Heart Failure

(2009) Elad Anter et al.   CIRCULATION

Diagnostic accuracy of clinical criteria for identifying systolic and diastolic heart failure: cross-sectional study

(2009) Ana Maestre et al.   JOURNAL OF EVALUATION IN CLINICAL PRACTICE